Cerebrospinal fluid P-tau181P: Biomarker for improved differential dementia diagnosis

Frontiers in Neurology

Volumn 6, Issue JUN, 2015, Pages

  Struyfs, Hanne ^a   Niemantsverdriet, Ellis ^a   Goossens, Joery ^a   Fransen, Erik ^b   Martin, Jean Jacques ^a   de Deyn, Peter P ^a,c,d   Engelborghs, Sebastiaan ^a,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Dementia; Differential diagnosis; Neuropathology; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; TAU PROTEIN[1-181]; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ELISA KIT; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84936942984     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00138     Document Type: Article

References (85)

1. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology (1984) 34:939-44. doi: 10.1212/WNL.34.7.939
2. Knopman DS, Dekosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the american academy of neurology. Neurology (2001) 56:1143-53. doi:10.1212/WNL.56.9.1143
3. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6:131-44. doi:10.1038/nrneurol.2010.4
4. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging (2010) 31:1867-76. doi:10.1016/j.neurobiolaging.2008.10.017
5. Engelborghs S, Le Bastard N. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther (2012) 16:135-41. doi:10.2165/11634170-000000000-00000
6. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2012) 123:1-11. doi:10.1007/s00401-011-0910-3
7. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol (2007) 114:5-22. doi:10.1007/s00401-007-0237-2
8. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2010) 119:1-4. doi:10.1007/s00401-009-0612-2
9. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol (2011) 122:111-3. doi:10.1007/s00401-011-0845-8
10. Markesbery WR. Neuropathology of Dementing Disorders. London: Arnold (1998).
11. Niemantsverdriet E, Struyfs H, Duits F, Teunissen C, Engelborghs S. Techniques, contraindications and complications of CSF collection procedures. In: Deisenhammer F, Sellebjerg F, Teunissen CE, Tumani H, editors. Cerebrospinal Fluid in Clinical Neurology. Cham, Switzerland: Springer International Publishing (2015). p. 35-57.
12. Engelborghs S, De Vreese K, Van De Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging (2008) 29:1143-59. doi:10.1016/j.neurobiolaging.2007.02.016
13. Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, et al. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. J Alzheimers Dis (2013) 33:807-22. doi:10.3233/JAD-2012-110029
14. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics (2011) 12:77. doi:10.1186/1471-2105-12-77
15. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol (2003) 60:1202-6. doi:10.1001/archneur.60.9.1202
16. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology (2004) 62:1580-4. doi:10.1212/01.WNL.0000123249.58898.E0
17. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord (2006) 21:9-15. doi:10.1159/000089137
18. De Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci (2006) 61:755-8. doi:10.1093/gerona/61.7.755
19. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 44:1472-80. doi:10.1515/CCLM.2006.258
20. Reijn TS, Rikkert MO, Van Geel WJ, De Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem (2007) 53:859-65. doi:10.1373/clinchem.2006.081679
21. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (2009) 116:203-12. doi:10.1007/s00702-008-0177-6
22. Yakushev I, Bartenstein P, Siessmeier T, Hiemke C, Scheurich A, Lotz J, et al. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord (2010) 30:245-53. doi:10.1159/000320206
23. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM. CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis (2011) 27:377-84. doi:10.3233/JAD-2011-110482
24. De Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry (2011) 82:240-6. doi:10.1136/jnnp.2010.207183
25. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia. J Alzheimers Dis (2011) 26:553-63. doi:10.3233/JAD-2011-110515
26. Gabelle A, Dumurgier J, Vercruysse O, Paquet C, Bombois S, Laplanche JL, et al. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis (2013) 34:297-305. doi:10.3233/JAD-121549
27. Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, et al. Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study. Am J Alzheimers Dis Other Demen (2013) 28:769-75. doi:10.1177/1533317513504615
28. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean? Alzheimers Dement (2014) 10(713-723):e712. doi:10.1016/j.jalz.2013.12.023
29. Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease. A large-scale international multicenter study. Alzheimers Dement (2015). doi:10.1016/j.jalz.2014.12.006
30. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the working group on: "molecular and biochemical markers of Alzheimer's disease". Neurobiol Aging (1998) 19:109-16.
31. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry (2003) 8:343-7. doi:10.1038/sj.mp.4001220
32. Satoh K, Shirabe S, Eguchi H, Tsujino A, Eguchi K, Satoh A, et al. 14-3-3 protein, total tau and phosphorylated tau in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease and neurodegenerative disease in Japan. Cell Mol Neurobiol (2006) 26:45-52. doi:10.1007/s10571-006-9370-z
33. Bahl JM, Heegaard NH, Falkenhorst G, Laursen H, Hogenhaven H, Molbak K, et al. The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging (2009) 30:1834-41. doi:10.1016/j.neurobiolaging.2008.01.013
34. Skillback T, Rosen C, Asztely F, Mattsson N, Blennow K, Zetterberg H. Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish mortality registry. JAMA Neurol (2014) 71:476-83. doi:10.1001/jamaneurol.2013.6455
35. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem (2015) 61:734-43. doi:10.1373/clinchem.2014.236679
36. Lehmann S, Gabelle A, Paquet C. Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis? Alzheimers Dement (2014). doi:10.1016/j.jalz.2014.09.003
37. Lehmann S, Delaby C, Paquet C, Gabelle A. Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. Clin Chem Lab Med (2015). doi:10.1515/cclm-2014-1232
38. Holsinger RM, Mclean CA, Collins SJ, Masters CL, Evin G. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol (2004) 55:898-9. doi:10.1002/ana.20144
39. Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology (2006) 67:710-2. doi:10.1212/01.wnl.0000229925.52203.4c
40. Verheijen JH, Huisman LG, Van Lent N, Neumann U, Paganetti P, Hack CE, et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem (2006) 52:1168-74. doi:10.1373/clinchem.2006.066720
41. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 64:718-26. doi:10.1001/archpsyc.64.6.718
42. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 65:1102-7. doi:10.1001/archneur.65.8.1102
43. Mulder SD, Van Der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis (2010) 20:253-60. doi:10.3233/JAD-2010-1367
44. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Neuromolecular Med (2012) 14:65-73. doi:10.1007/s12017-012-8171-4
45. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, et al. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 183:74-80. doi:10.1016/S0014-4886(03)00027-X
46. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, et al. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res (2010) 1357:175-83. doi:10.1016/j.brainres.2010.08.022
47. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis (2010) 21:1119-28. doi:10.3233/JAD-2010-100207
48. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2010) 15:138-45. doi:10.1038/mp.2008.84
49. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis (2011) 24:537-46. doi:10.3233/JAD-2011-101878
50. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology (2011) 77:35-8. doi:10.1212/WNL.0b013e318221ad47
51. Lewczuk P, Popp J, Lelental N, Kolsch H, Maier W, Kornhuber J, et al. Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer's disease. J Alzheimers Dis (2012) 28:119-25. doi:10.3233/JAD-2011-110857
52. Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med (1998) 4:832-4. doi:10.1038/nm0798-832
53. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 102:2273-6. doi:10.1073/pnas.0409336102
54. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 14:837-42. doi:10.1038/nm1782
55. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, et al. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J (2010) 24:2716-26. doi:10.1096/fj.09-150359
56. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, et al. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One. (2010) 5:e15725. doi:10.1371/journal.pone.0015725
57. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, et al. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis (2012) 29:171-6. doi:10.3233/JAD-2012-111361
58. Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, et al. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem (2013) 433:112-20. doi:10.1016/j.ab.2012.09.014
59. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, et al. Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol (2013) 70:594-9. doi:10.1001/jamaneurol.2013.48
60. Yang T, Hong S, O'malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement (2013) 9:99-112. doi:10.1016/j.jalz.2012.11.005
61. Steinacker P, Hendrich C, Sperfeld AD, Jesse S, Von Arnim CA, Lehnert S, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol (2008) 65:1481-7. doi:10.1001/archneur.65.11.1481
62. Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener (2014) 15:351-6. doi:10.3109/21678421.2014.905606
63. Suarez-Calvet M, Dols-Icardo O, Llado A, Sanchez-Valle R, Hernandez I, Amer G, et al. Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. J Neurol Neurosurg Psychiatry (2014) 85:684-91. doi:10.1136/jnnp-2013-305972
64. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology (2008) 71:1235-9. doi:10.1212/01.wnl.0000325058.10218.fc
65. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, Van Swieten J, et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol (2008) 181:37-41. doi:10.1083/jcb.200712039
66. Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol (2010) 69:1191-200. doi:10.1097/NEN.0b013e3181fc9aea
67. Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 4:683-99. doi:10.2217/bmm.10.90
68. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 69:570-80. doi:10.1002/ana.22311
69. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging (2012) 33(430):e431-3. doi:10.1016/j.neurobiolaging.2010.12.001
70. Kapaki E, Paraskevas GP, Emmanouilidou E, Vekrellis K. The diagnostic value of CSF alpha-synuclein in the differential diagnosis of dementia with Lewy bodies vs. normal subjects and patients with Alzheimer's disease. PLoS One (2013) 8:e81654. doi:10.1371/journal.pone.0081654
71. Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, et al. Increased CSF alpha-synuclein levels in Alzheimer's disease: correlation with tau levels. Alzheimers Dement (2014) 10(5 Suppl):S290-8. doi:10.1016/j.jalz.2013.10.004
72. Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One (2013) 8:e53250. doi:10.1371/journal.pone.0053250
73. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, et al. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke (2004) 35:e159-62. doi:10.1161/01.STR.0000127420.10990.76
74. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol (2009) 8:205-16. doi:10.1016/S1474-4422(09)70016-X
75. Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, et al. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol (2015) 72:267-75. doi:10.1001/jamaneurol.2014.4068
76. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 6:455-76. doi:10.2217/bmm.12.42
77. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 8:20. doi:10.1186/1750-1326-8-20
78. Roh JH, Lee JH. Recent updates on subcortical ischemic vascular dementia. J Stroke (2014) 16:18-26. doi:10.5853/jos.2014.16.1.18
79. Schade S, Mollenhauer B. Biomarkers in biological fluids for dementia with Lewy bodies. Alzheimers Res Ther (2014) 6:72. doi:10.1186/s13195-014-0072-3
80. Oeckl P, Steinacker P, Feneberg E, Otto M. Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: current status and future perspectives. Biochim Biophys Acta (2015) 1854:757-68. doi:10.1016/j.bbapap.2014.12.010
81. Schoonenboom NS, Van Der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging (2008) 29:669-75. doi:10.1016/j.neurobiolaging.2006.11.018
82. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 16:351-62. doi:10.3233/JAD-2009-0968
83. Vos S, Van R I, Burns L, Knol D, Scheltens P, Soininen H, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging (2012) 33:2272-81. doi:10.1016/j.neurobiolaging.2011.12.017
84. Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage (2012) 62:229-38. doi:10.1016/j.neuroimage.2012.04.056
85. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2013) 266:583-91. doi:10.1148/radiol.12120010